Onconova Therapeutics, Inc., a biopharmaceutical company discovering and developing novel cancer treatments with a focus on myelodysplastic syndromes (MDS), has entered into a Distribution, License, and Supply Agreement granting Specialized Therapeutics Asia (STA) exclusive rights to commercialize rigosertib in Australia and New Zealand. Onconova may be entitled to receive clinical, regulatory, and sales-based milestones of as much as $30.4 million and royalties on net sales. “We are pleased ...